Cell Therapy for Degenerative Retinal Disease: Special Focus on Cell Fusion-Mediated Regeneration

2019 ◽  
pp. 217-244
Author(s):  
Francesco Sottile ◽  
Martina Pesaresi ◽  
Giacoma Simonte ◽  
Maria Pia Cosma
Keyword(s):  
Cell Therapy ◽  
Cell Fusion ◽  
Retinal Disease ◽  
Special Focus

scholarly journals Virus-Mediated Cell-Cell Fusion

2020 ◽  
Vol 21 (24) ◽  
pp. 9644
Author(s):  
Héloïse Leroy ◽  
Mingyu Han ◽  
Marie Woottum ◽  
Lucie Bracq ◽  
Jérôme Bouchet ◽  
...  
Keyword(s):  
Cell Fusion ◽  
Fusion Proteins ◽  
Target Cells ◽  
Special Focus ◽  
Human Pathogens ◽  
General Process ◽  
Tissue Organization ◽  
Donor Cells ◽  
Infected Cells ◽  
Cell Cell

Cell-cell fusion between eukaryotic cells is a general process involved in many physiological and pathological conditions, including infections by bacteria, parasites, and viruses. As obligate intracellular pathogens, viruses use intracellular machineries and pathways for efficient replication in their host target cells. Interestingly, certain viruses, and, more especially, enveloped viruses belonging to different viral families and including human pathogens, can mediate cell-cell fusion between infected cells and neighboring non-infected cells. Depending of the cellular environment and tissue organization, this virus-mediated cell-cell fusion leads to the merge of membrane and cytoplasm contents and formation of multinucleated cells, also called syncytia, that can express high amount of viral antigens in tissues and organs of infected hosts. This ability of some viruses to trigger cell-cell fusion between infected cells as virus-donor cells and surrounding non-infected target cells is mainly related to virus-encoded fusion proteins, known as viral fusogens displaying high fusogenic properties, and expressed at the cell surface of the virus-donor cells. Virus-induced cell-cell fusion is then mediated by interactions of these viral fusion proteins with surface molecules or receptors involved in virus entry and expressed on neighboring non-infected cells. Thus, the goal of this review is to give an overview of the different animal virus families, with a more special focus on human pathogens, that can trigger cell-cell fusion.

Stem cell therapy for retinal disease

2012 ◽  
Vol 23 (3) ◽  
pp. 226-234 ◽  
Author(s):  
Michael D. Tibbetts ◽  
Michael A. Samuel ◽  
Tom S. Chang ◽  
Allen C. Ho
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Retinal Disease

Stem-cell therapy in retinal disease

2009 ◽  
Vol 20 (3) ◽  
pp. 175-181 ◽  
Author(s):  
Paul S Baker ◽  
Gary C Brown
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Retinal Disease

scholarly journals Autologous stem cell therapy for inherited and acquired retinal disease

2018 ◽  
Vol 13 (1) ◽  
pp. 89-96 ◽  
Author(s):  
Mary Ben L Apatoff ◽  
Jesse D Sengillo ◽  
Eugenia C White ◽  
Mathieu F Bakhoum ◽  
Alexander G Bassuk ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Retinal Disease

Cell therapy for retinal disease

2016 ◽  
Vol 27 (3) ◽  
pp. 185-190 ◽  
Author(s):  
David Ehmann ◽  
Abtin Shahlaee ◽  
Allen C. Ho
Keyword(s):  
Cell Therapy ◽  
Retinal Disease

scholarly journals Surgical Approaches to Gene and Stem Cell Therapy for Retinal Disease

2011 ◽  
Vol 22 (5) ◽  
pp. 531-535 ◽  
Author(s):  
J. Timothy Stout ◽  
Peter J. Francis
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Retinal Disease ◽  
Surgical Approaches

Stem cell therapy for age-related retinal disease

Aging Health ◽  
2009 ◽  
Vol 5 (6) ◽  
pp. 799-811
Author(s):  
Enrique Garcia-Valenzuela ◽  
Swarupa Kancherla ◽  
Alejandra Lopez ◽  
Cathleen A Davidson
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Retinal Disease ◽  
Age Related

scholarly journals MECHANISMS IN ENDOCRINOLOGY: Towards the clinical translation of stem cell therapy for type 1 diabetes

2017 ◽  
Vol 177 (4) ◽  
pp. R159-R168 ◽  
Author(s):  
Daniel Espes ◽  
Joey Lau ◽  
Per-Ola Carlsson
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Clinical Translation ◽  
Special Focus ◽  
Insulin Producing Cells ◽  
Potential Risks

Insulin-producing cells derived from human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) have for long been a promising, but elusive treatment far from clinical translation into type 1 diabetes therapy. However, the field is now on the verge of moving such insulin-producing cells into clinical trials. Although stem cell therapies provide great opportunities, there are also potential risks such as teratoma formation associated with the treatment. Many considerations are needed on how to proceed with clinical translation, including whether to use hESCs or iPSCs, and whether encapsulation of tissue will be needed. This review aims to give an overview of the current knowledge of stem cell therapy outcomes in animal models of type 1 diabetes and a proposed road map towards the clinical setting with special focus on the potential risks and hurdles which needs to be considered. From a clinical point of view, transplantation of insulin-producing cells derived from stem cells must be performed without immune suppression in order to be an attractive treatment option. Although costly and highly labour intensive, patient-derived iPSCs would be the only solution, if not clinically successful encapsulation or tolerance induction protocols are introduced.

Sign in / Sign up

Export Citation Format

Share Document